Blockchain Registration Transaction Record
Helus Pharma CEO to Present at Cantor Conference
Helus Pharma CEO Michael Halstead to speak at Cantor Healthcare Conference Sept 11. Learn about their novel serotonergic agonists for depression and anxiety.
This news matters because it highlights Helus Pharma's active engagement with the investment community, potentially increasing visibility and investor interest in their promising psychedelic-derived treatments for mental health. With Phase 3 data on HLP003 for major depressive disorder and a Breakthrough Therapy Designation, the company could significantly impact the treatment landscape if approved. Investors and patients alike should watch for updates from the conference as they may signal progress and future developments.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0xe053c587988c2d8491b2e074a144f81c461febb262ff05f7ddb1aa43d951be49 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | sageGIEz-a6558124ecb2690484ff4aff17a3265f |